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Chronic lymphocytic leukemia (CLL) is a common adult leukemia caused by abnormal 
accumulation of B cells. Raval et al. (2007) now implicate dowregulation of the expression 
of the kinase DAPK1 both genetically and epigenetically in familial and sporadic CLL.Chronic lymphocytic leukemia (CLL) 
was thought to be a homogene-
ous disease of immature immune-
incompetent B cells with minimal 
proliferative capacity, which accu-
mulate because they are unable to 
undergo apoptosis. With increasing 
knowledge of the genetic lesions 
and signaling pathways involved, 
CLL is now considered a more het-
erogeneous leukemia that originates 
from antigen-stimulated B cells that 
escape normal cell death mecha-
nisms and/or undergo increased 
proliferation (Chiorazzi et al., 2005) 
due to aberrant activity of ZAP70, 
a Src family protein tyrosine kinase 
normally only expressed in T cells. 
Interestingly, CLL is a familial dis-
ease in a relatively high proportion 
(10%–20%) of patients indicating an 
underlying genetic susceptibility for 
developing malignant lymphopro-
liferation. However, genome-wide 
screening of families with CLL has 
not identified clear candidate genes 
(Sellick et al., 2006).Epigenetic regulation of gene 
expression—which is crucial for 
both normal and malignant develop-
ment of cells—has been implicated 
in CLL (Calin et al., 2005). Epigenet-
ics affects all aspects of tumor cell 
biology including cell growth, cell 
cycle control, differentiation, DNA 
repair, apoptosis, and cell death. 
Epigenetic regulation by, for exam-
ple, promoter methylation, micro-
RNAs, or histone modifications not 
only influences expression of indi-
vidual genes but also may affect 
whole cellular programs such as 
hematopoietic differentiation (Chen 
et al., 2004). Consequently, epige-
netic modulation of gene expression 
has become a target for therapeutic 
intervention (Bhalla, 2005).
In this issue of Cell, a consortium 
led by Christoph Plass and Albert 
de la Chapelle presents results from 
their search to find genes involved 
in aberrant cellular proliferation, dif-
ferentiation, and apoptosis in CLL 
(Raval et al., 2007). They identified Cell 12DAP kinase 1 (DAPK1) as a can-
didate gene silenced in all cases 
of CLL. Epigenetic silencing of 
DAPK through promoter methyla-
tion occurred in almost all sporadic 
cases of CLL. Furthermore, in a 
large family with several affected 
individuals, a mutation/polymor-
phism in the promoter of DAPK1 
was identified as causing persistent 
downregulation of DAPK1 expres-
sion due to increased binding of the 
HOXB7 transcriptional repressor. 
This study identifies a single gene 
as being affected by genetic and 
epigenetic alterations in each case 
of CLL analyzed and provides evi-
dence for the genetic susceptibility 
of this disease.
Several functions for DAPK1 in 
differentiation and cell death have 
been described (Bialik and Kimchi, 
2006). Initially, DAPK was cloned 
as a serine/threonine kinase asso-
ciated with the cytoskeleton and 
identified as a mediator of cell death 
induced by interferon γ. DAPK1 is 9, June 1, 2007 ©2007 Elsevier Inc. 853
figure 1. DAPK1 in Homeostasis of normal and CLL B Cells
Homeostasis in B cells that are triggered by the interaction between immunoglobulin (Ig) receptor and antigen is maintained by a delicate 
balance between proliferation and apoptosis. The serine/threonine kinase DAPK1 increases and/or synergizes with cell death signaling to 
ensure the balance between proliferation and cell death in individual B cell clones in a wild-type situation. Although aberrant expression 
of ZAP70 (observed in CLL) may drive increased proliferation, this event is opposed by intact death receptor and mitochondria-depend-
ent apoptosis pathways. In sporadic cases of CLL, the B cell population is heterogeneous with normal B cells (yellow) as well as a few 
(clonal, premalignant?) B cells in which DAPK1 is epigenetically silenced. When these B cells are activated by antigen, proliferation is not 
effectively offset by apoptosis and increased expansion of the clone ensues. In the case of familial CLL, the intrinsic apoptosis defect 
mediated by downregulated DAPK1 expression—caused by increased binding of the HoxB7 transcriptional repressor to a mutated DAPK1 
promoter—is already present in the germline. Thus, B cells are more susceptible to clonal expansion and secondary hits associated with 
malignant transformation.also involved in several pathways 
mediating apoptosis, although 
its precise function in the extrin-
sic (death receptor-dependent) or 
intrinsic (mitochondria-dependent) 
pathways remains unclear. Also, no 
direct physical interactions between 
DAPK1 and adaptor proteins (such 
as FADD and APAF1), inititator cas-
pases, or effector caspases have 
been shown. Other functions of 
DAPK1 include suppression of inva-
sion and metastasis, which may be 
related to its association with the 
cell cytoskeleton (Inbal et al., 1997). 
Thus DAPK1 may act as an initita-
tor of signaling pathways that sup-
press a malignant phenotype and 
facilitate triggering of programmed 
cell death. 
How does one incorporate the 
results from Raval et al. into patho-
genesis and treatment of CLL? 
Resistance to treatment is a hall-
mark of CLL, and resistance to 
chemotherapy has been attributed 
to deregulated expression of apop-
tosis regulators. Increased expres-
sion of the apoptotic inhibitor Bcl2 
found in CLL may be due to lack 
of expression of microRNAs sup-
pressing Bcl2 expression (Calin et 
al., 2005). CLL cells were also found 
to be resistant to induction of apop-
tosis by the apoptosis-inducing 
ligand TRAIL, considered of high 854 Cell 129, June 1, 2007 ©2007 Elsevietherapeutic value in many tumors. 
Epigenetic modification of gene 
expression by HDAC inhibitors is 
able to revert apoptosis resistance, 
and HDAC inhibitors have already 
been introduced into clinical stud-
ies in CLL (Inoue et al., 2006). The 
observation that a proapoptotic 
cell death modifier such as DAPK is 
epigenetically silenced in CLL and 
may be responsible for the death-
less phenotype, and resistance to 
apoptosis provides a new twist. 
The fact that DAPK1 expression is 
downregulated in a variety of dif-
ferent tumors supports the general 
concept that evasion from death 
programs is a general hallmark of 
cancer cells (Calmon et al., 2007; 
Holleman et al., 2006).
However, we are left with two 
questions. First, where do we place 
DAPK in the process of malignant 
transformation of precursors en 
route to overt “benign” or “malig-
nant” CLL? Most likely, silencing 
of DAPK1 occurs at an early stage 
of the malignant process, because 
CLL cells have to escape cell death 
control and apoptosis during the 
sequential steps of acquisition of 
the malignant potential (Figure 1). 
Thus, DAPK1 deficiency—either 
through a genetic mutation or 
aberrant epigenetic regulation—is 
probably a prerequisite for further r Inc.aberrant regulation of cellular pro-
grams. The fact that epigenetic 
regulation, for example by altered 
promoter methylation, are inher-
ited like any other gene function, 
also provides a new perspective 
on genetic susceptibility to tumor 
formation with the potential of a 
deeper understanding of cancer 
susceptibility genes. The second 
question that remains is whether 
or not restoration of DAPK1 func-
tion will reinstate the cell death 
sensitivity of CLL cells irrespective 
of the “benign” and the aggres-
sive subtype. The answer to this 
question remains to be determined 
experimentally and may prove to be 
effective in treating this disease.
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mier, K.M., Janka-Schaub, G.E., Gobel, U., 
Graubner, U.B., Evans, W.E., et al. (2006). At least 11 distinct functional classes 
of proteins—including the Raf serine/
threonine kinases and the p110 cata-
lytic subunits of class I PI3Ks—have 
been implicated as effectors of the 
small GTPase Ras (Repasky et al., 
2004). Because of the frequent muta-
tional activation of Ras in cancer and 
the vast number of its effectors (Fig-
ure 1), there has been much debate 
regarding the most effective strate-
gies to develop anti-Ras inhibitors. In 
this issue, Gupta et al. (2007) further 
validate the importance of p110α and 
the PI3K-Akt signaling pathway in 
Ras-induced tumorigenesis.
The majority of studies analyzing 
a role for effectors in Ras-mediated 
oncogenesis have been performed in 
cultured cells. For example, experi-
ments in immortalized human epi-
thelial cells ectopically expressing 
oncogenic Ras have shown that 
concurrent activities of Raf, PI3K, 
and Ral-GEF (guanine nucleotide 
exchange factor) effector pathways 
are required for Ras-mediated initia-
tion of tumor growth. The PI3K path-
stopping Ras 
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way is also crucial for tumor mainte-
nance (Lim and Counter, 2005). One 
recent study used RNA interference 
to demonstrate the necessity of the 
Ral-GEF-Ral pathway in tumorigene-
sis, invasion, and metastasis of KRAS 
mutation positive pancreatic carci-
noma cell lines (Lim et al., 2005).
Genetically engineered mouse 
models have also validated the impor-
tance of Ras effectors (Repasky et al., 
2004). Mice deficient for the effectors 
Tiam1, PLCε, or Ral-GDS showed 
impaired tumor initiation when tested 
in skin tumorigenesis—induced by the 
carcinogen dimethybenzanthracine 
(DMBA)—in which H-Ras activation is 
causal and frequent. Genetic ablation 
of other Ras effectors, in particular 
of p110α and p110β, results in defec-
tive development, thus complicat-
ing analyses of their contributions to 
Ras-mediated cancer development. 
Furthermore, deficiency studies can 
only assess the requirement of a given 
factor for tumorigenesis and not the 
specific interactions involved. Thus, 
Gupta et al. (2007) engineered mice in 
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which the endogenous PIK3CA gene 
encodes a mutant p110α protein that 
is enzymatically active, but cannot 
interact with Ras, to evaluate the role 
of this effector in endogenous normal 
and mutant Ras signaling.
To selectively ablate p110α inter-
actions with Ras, Gupta et al. (2007) 
introduced missense mutations into 
the germline sequence specifying the 
Ras-binding domain of p110α. Viable 
mice homozygous for this PIK3CA 
mutant allele were obtained, indi-
cating that this partial loss-of-func-
tion mutant of p110α was sufficient 
to support development. They then 
analyzed these PIK3CA mutants in 
two well-characterized Ras-driven 
tumor models. In the K-Ras LA2 
mouse model (Johnson et al., 2001), 
tumorigenesis is driven by endog-
enous levels of mutant K-Ras (G12D) 
expression, and these mice develop 
lung adenocarcinomas at a high fre-
quency. When the K-Ras LA2 mice 
were crossed with mice homozygous 
for mutant PIK3CA, a striking 95% 
reduction in lung tumor forma-
hapel Hill, NC 27599, USA
mplex cytoplasmic signaling 
 Ras-mediated tumorigenesis 
hosphatidylinositol 3-kinase 
. This result will stimulate re-
ancer treatment.
